Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies)

v3.10.0.1
Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies)
9 Months Ended
Sep. 30, 2018
Policies  
Research and Development

Research and Development

 

Research and development costs are expensed as incurred. The majority of the Company’s research and development costs consist of clinical study expenses. These consist of fees, charges, and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. External clinical studies expenses were $2,256,291 and $1,355,085  for the nine months ended September 30, 2018 and 2017, respectively.